Citi slashes Human Genome target on slow Benlysta sales

Doctors aren't flocking to Benlysta, the new lupus treatment developed by Human Genome Sciences ($HGSI) and marketed in partnership with GlaxoSmithKline ($GSK), Citi analyst Dr. Yaron Werber says in a new note to investors. As the Associated Press reports, Werber cut his price target on HGS stock to $15 from $26 on the slow uptake. Report

Suggested Articles

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.